Skip to main content
    A

    Alto Neuroscience, Inc. (ANRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $24.92
    -2.20 (-8.11%)

    Market Cap: $1.09B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Alto Neuroscience, Inc. (ANRO) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Alto Neuroscience (ANRO) has a market cap of $1.09B and an enterprise value of $784.44M. Its share count is up 71.68% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 27.89% below the market cap, as cash exceeds debt.

    Market Cap$1.09B
    Enterprise Value$784.44M
    Latest price (Nov 17, 2026)$24.92

    Key Dates

    Last Earnings DateNov 10, 2026
    Fiscal Year EndSeptember

    Share Statistics

    The share count rose 8.68% in the quarter ended Sep 30, 2026 and grew 31.38% a year over 2 years.

    Shares Outstanding46.53M
    Shares Change (YoY)+71.68%
    Shares Change (QoQ)+8.68%
    Share Count Growth (2Y CAGR)+31.38%

    Price Statistics

    The stock is up 105.78% over 52 weeks and trades 4.08% below its 50-day average.

    Beta (1Y)1.78
    52-Week Change+105.78%
    1-Month Change+9.20%
    3-Month Change-28.58%
    6-Month Change+21.86%
    Total Return (1Y)+105.78%
    Return vs SPY (1Y)+57.39%
    Max Drawdown (1Y)-40.75%
    Max Drawdown (3Y)-91.74%
    Sharpe Ratio (1Y)0.72
    Correlation with SPY (1Y)0.34
    50-Day Average$25.98
    200-Day Average$24.84
    52-Week Range$12.51 to $37.48
    RSI (14 Days)47.3
    Average Volume (20 Days)597.64K

    Price chart

    Financial Position

    Current assets cover 18.12x current liabilities, and total debt is 0.05x shareholder equity.

    Current Ratio18.12x
    Quick Ratio18.12x
    Debt / Equity0.05x
    Interest Coverage-44.89x

    Returns and Efficiency

    Return on invested capital is -23.54% over the last 12 months, against a 5-year average of 25.25%.

    Return on Equity (ROE)-32.10%
    Return on Assets (ROA)-29.15%
    Return on Invested Capital (ROIC)-23.54%
    Return on Capital Employed (ROCE)-30.16%
    ROA (5Y Average)-39.43%
    ROIC (5Y Average)25.25%

    Scores

    ANRO has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Operating Income$32.18M
    Pretax Income-$95.18M
    Net Income-$95.18M
    EBIT-$93.11M
    Reported EPS (TTM)-$2.44

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 90.82% of the $326.50M in total assets.

    Cash and Equivalents$319.34M
    Total Debt$15.98M
    Net Cash$303.36M
    Net Cash Per Share$6.52
    Working Capital$305.36M
    Shareholder Equity$296.53M
    Book Value Per Share$6.37
    Total Assets$326.50M
    Total Liabilities$29.98M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $556.00K of capital spending, operating cash flow left -$79.68M of free cash flow.

    Operating Cash Flow-$79.12M
    Capital Expenditures$556.00K
    Free Cash Flow-$79.68M
    FCF Per Share-$1.99
    Depreciation and Amortization$1.74M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Peer Position

    Against 6 similar companies, ANRO has the 4th highest ROIC.

    ROIC-23.54% vs -42.31% median
    Revenue Growth (Trailing 4 Quarters, YoY)-100.00% vs -16.64% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About ANRO

    What is ANRO's market cap?

    Alto Neuroscience has a market cap of $1.09B. Its enterprise value, which adds debt and subtracts cash, is $784.44M.

    How many shares of ANRO are outstanding?

    Alto Neuroscience has 46.53M shares outstanding. The count is up 71.68% from a year earlier.

    Does ANRO pay a dividend?

    No. Alto Neuroscience does not pay a dividend.

    How much debt does ANRO have?

    Alto Neuroscience has $15.98M of total debt and $319.34M of cash and equivalents, a net cash position of $303.36M.